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Mast Cells Are Key Mediators of Cathelicidin-Initiated
Skin Inflammation in Rosacea
Yumiko Muto1, Zhenping Wang1, Matthieu Vanderberghe1, Aimee Two1, Richard L. Gallo1 and
Anna Di Nardo1
Rosacea is a chronic inflammatory skin disease whose pathophysiological mechanism is still unclear. However,
it is known that mast cell (MC) numbers are increased in the dermis of rosacea patients. MC proteases not
only recruit other immune cells, which amplify the inflammatory response, but also cause vasodilation and
angiogenesis. MCs are also one of the primary sources of cathelicidin LL-37 (Cath LL-37), an antimicrobial peptide
that has been shown to be an enabler of rosacea pathogenesis. Here, we demonstrate that MCs are key mediators
of cathelicidin-initiated skin inflammation. After Cath LL-37 injection into the dermis, MC-deficient B6.Cg-KitW-sh/
HNihrJaeBsmJ (KitW-sh) mice did not develop rosacea-like features. Conversely, chymase (Po0.001), tryptase, and
Mmp9 (Po0.01) mRNA levels were significantly higher in C57BL/6 wild-type (WT) mice. Treating WTmice with an
MC stabilizer significantly decreased the expressions of Mmp9 and Cxcl2 (Po0.01). Our data were confirmed on
erythematotelangiectatic rosacea subjects who showed a decrease in matrix metalloproteinase activity (Po0.05),
after 8 weeks of topical cromolyn treatment. We conclude that MCs have a central role in the development of
inflammation subsequent to Cath LL-37 activation and that downregulation of activated MCs may be a therapy for
rosacea treatment.
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INTRODUCTION
Rosacea is a chronic inflammatory skin disease that affects
B16 million Americans (The National Rosacea Society,
http://www.rosacea.org/). Flares often occur without specific
triggers, and when left untreated they can take weeks to
subside (Scharschmidt et al., 2010). The formation of an
aberrant form of antimicrobial peptide, cathelicidin LL-37
(Cath LL-37), on the surface of the skin has been previously
implicated as a key initiator of rosacea (Yamasaki et al., 2007).
Cath LL-37 in the skin is also implicated in a wide range of
inflammatory diseases including atopic dermatitis (Ong et al.,
2002) and psoriasis (Lande et al., 2007). The active form of
cathelicidin LL-37 peptide is not only able to kill microbes
but is also able to modify host immunity and growth responses
by promoting leukocyte chemotaxis (De et al., 2000) and
angiogenesis (Koczulla et al., 2003), and it can alter the
expression of extracellular matrix components (Park et al.,
2009). In rosacea, the formation of an aberrant form of Cath
LL-37 on the surface of the skin has been attributed to the
overactivity of the kallikrein-related peptidases (KLKs), which
are a family of tryptic serine proteases that are responsible for
generating Cath LL-37 from its precursor protein, hCAP18, in
the epidermis (Yamasaki et al., 2007; Yamasaki and Gallo,
2008). In an animal model, intradermal injection of Cath
LL-37, but not mouse cathelicidin, induced an inflammatory
response with rosacea-like features (Yamasaki et al., 2007).
Interestingly, subantimicrobial doses (40 mg per day) of
doxycycline, a proven treatment for human rosacea, directly
inhibits matrix metalloproteinases (MMPs), which in turn
inhibits the activity of KLKs and prevents the activation of
cathelicidins in human epidermal keratinocytes (Korting and
Schollmann, 2009; Kanada et al., 2012). Therefore, Cath LL-37
has emerged as a key mediator in the pathogenesis of rosacea.
Many studies have proven that mast cells (MCs) are able to
enhance host defense through direct effects on pathogens by
initiating the inflammation associated with innate immune
responses (Galli et al., 2008). Although MCs can contribute to
overall host protection by releasing a variety of molecules,
including tumor necrosis factor-a (McLachlan et al., 2008),
leukotriene B4 (Malaviya and Abraham, 2000), and
cathelicidin AMP (Di Nardo et al., 2003), accumulated
studies have also specifically implicated MCs in the develop-
ment of inflammation in the skin (Thurmond et al., 2008;
Kawakami et al., 2009; Lin et al., 2011). Most importantly, in
the context of our study, MCs have been observed in
increased numbers in the skin lesions of rosacea patients.
Until now, however, there has been no clear proof of the
direct connection between MCs and rosacea formation.
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In addition to inflammation, neuronal dysregulation is
equally important to rosacea pathogenesis. In fact, neuronal
dysregulation contributes to the disease via various mechan-
isms, such as vasomotor instability, release of proinflammatory
neuropeptides (NPs), and neuronal injury (Roosterman et al.,
2006; Wang et al., 2008). MCs can also be activated by NPs to
release their components upon cell degranulation. NPs have
also been shown to induce the production of tumor necrosis
factor-a, CCL2, CCL5, CXCL9, CXCL10, and CXCL8 in human
MCs (Kulka et al., 2008), which leads to the recruitment of
dendritic cells/macrophages (via CCL2), TH1 lymphocytes (via
CCL5, CXCL9, or CXCL10), and neutrophils (via CXCL8)
(Gangavarapu et al., 2012). In the current study, we show
that NPs induce MC enzyme activation and subsequent
Cath LL-37 generation from hCAP18. On the basis of these
results, it is likely that MCs are mediators of the stress-response
network in skin inflammation (Arck et al., 2006). Considering
previous studies of the role of MCs in rosacea, we propose that
MCs and MC proteases have critical functions during the
development of skin inflammation in rosacea. Furthermore,
understanding the in vivo connections between MCs,
epidermal keratinocytes, and sensory nerves, respectively,
may lead to a better interpretation of the pathophysiology of
rosacea.
RESULTS
MC-deficient mice do not develop inflammation following Cath
LL-37 injection in the skin
To verify that MC proteases are increased in rosacea skin,
biopsies from six rosacea patients and six healthy control
volunteers were collected and CMA1 (chymase gene) and
MMP9 (metalloprotease 9 gene) mRNA expressions were
measured as essential markers of MC presence and activation
(Tchougounova et al., 2005). Both CMA1 and MMP9 mRNA
levels showed significant increases in rosacea skin (n¼6)
compared with healthy skin (n¼ 6) (Figure 1a).
This means that MCs were abnormally activated and were
specifically expressing enzymes involved in Cath LL-37
processing.
To prove that MCs are central to the pathogenesis of
rosacea inflammation, we used a well-established mouse
model of rosacea-like inflammation (Yamasaki et al., 2007).
We injected Cath LL-37 intradermally into MC-deficient
mice B6.Cg-KitW-sh/HNihrJaeBsmJ (KitW-sh) and compared
the resulting inflammation with wild-type (WT) mice. Our
clinical endpoint observation (at 72 hours) showed, as pre-
viously described, inflammation in the skin of WT mice
injected with Cath LL-37, whereas KitW-sh mice did
not develop any rosacea-like features (Figure 1b). To further
establish the essential role of MCs in the observed phenotype,
we reconstituted the MC-deficient mice with WT MCs and
repeated the injections with Cath LL-37. To define the
specificity of Cath LL-37 in MC activation, we also included
a Cath LL-37 scrambled peptide in the experiments. Our
results showed that, after Cath LL-37 challenge, Mmp9 mRNA
expression in skin from MC-deficient mice was significantly
lower than in skin from WT (Po0.01) and WT MC-recon-
stituted KitW-sh mice (Po0.05). There was no significant
difference observed between any of the mouse groups when
Cath LL-37 scrambled peptide was used (Figure 1c). We also
injected different concentrations (50 and 320mM) of Cath
LL-37 peptide into WT mice and demonstrated that Cath
LL-37 induced an increase in MMP activity in a dose-
dependent manner in WT mice (Figure 1d). Furthermore,
a time-course experiment showed that mRNA of the MC-
specific proteases chymase and tryptase were expressed
immediately after injection of Cath LL-37, whereas the same
enzymes were not detectable in the skin of the MC-deficient
mice (Figure 1e).
Mouse MCs (mMCs) release MMP-9 and IL-6 in response to Cath
LL-37
To confirm that MCs are responsive to direct Cath LL-37
stimulation, bone marrow–derived mouse MCs (mMCs) were
stimulated with different concentrations of Cath LL-37 at
different time points. Mmp9, Cma1 (the gene for Chymase),
and Tpsab1 (the gene for Tryptase) mRNA expressions were
significantly higher at 5 hours (Po0.001; Figure 2a), whereas
Mmp-1a, Klk5, and Klk6 were not detectable at 5 hours (data
not shown). There were no differences in MMP9, Cma1, and
Tpsab1 mRNA expressions with different Cath LL-37 concen-
trations at 24 hours (data not shown). MMP-9 protease activity
in the culture medium of MCs stimulated with Cath LL-37 for
24 hours was confirmed by fluorescence enzymatic activity
assay using an MMP-specific substrate and an MMP-9-specific
inhibitor (Figure 2b). In Figure 2b, the difference between the
two curves indicates MMP-9-specific activity. MC degranula-
tion was confirmed by measuring b-hexosaminidase release in
Cath LL-37-stimulated MC supernatants. We also found that a
very low concentration of Cath LL-37 (20 nM) was enough to
induce degranulation (Figure 2c). In addition, ELISA detected
high levels of secreted IL-6 in mMCs after 24 and 48 hours of
stimulation with different Cath LL-37 concentrations (20 and
40 nM; Figure 2d). IL-6 increase was also confirmed in vivo.
In fact, Il6 mRNA expression was also observed in the
skin from WT mice, but not in MC-deficient mice, after
Cath LL-37 challenge (Figure 2e).
NPs activate tryptic-MC serine proteases in WT mouse skin
Rosacea flare-ups are frequently initiated by face flushing due
to neuronal dysfunction and increased release of pituitary
adenylate cyclase–activating peptide (PACAP; Schwab et al.,
2011). To investigate whether NPs require MC activation for
the development of the inflammatory response in rosacea,
100ml of 1mM NPs (substance P: SP; adrenomedullin-2: ADM-
2; Pituitary adenylate cyclase–activating peptide: PACAP)
were injected intradermally into WT and MC-deficient mice.
After 6 hours from the NP challenge, skin biopsies were taken
and processed for mRNA expression analysis. Tryptase mRNA
expression was observed to be markedly increased by PACAP
stimulation (Po0.01) in WT mice. Cma1, Tpsab1, Mmp1a,
and Mmp9 were also significantly increased (Po0.05) in
WT mice (Figure 2f), but not as substantially as PACAP. In
addition, mRNA expressions of the proinflammatory cytokines
Cxcl2 (mouse homolog of human IL8) and Tnf (gene for tumor
necrosis factor-a) were also significantly increased with
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PACAP challenge in WT mice, but not in MC-deficient mice
(Po0.01; Figure 2g). These results prove that neurovascular
alteration and neuropeptide release during a face flushing can
be translated to rosacea inflammation in skin through the
activation of MC enzymes. Moreover, these same MC
enzymes can further increase the levels of free Cath LL-37
and amplify the inflammatory response.
MC stabilizer suppresses the development of rosacea-like
inflammation in vivo
According to the obtained results, MC proteases and MMP-9,
which are released from MCs upon stimulation by Cath LL-37,
are central in promoting rosacea-like skin inflammation.
Therefore, we anticipated that blocking MC degranulation
would also prevent the formation of rosacea-like inflammation
in the skin. To test this hypothesis, cromolyn sodium, a very
well known MC stabilizer, was injected intraperitoneally into
WT mice (10 mg kg1 body weight, per day) for 4 days before
Cath LL-37 challenge. At 24 hours after the last cromolyn
sodium injection, mice were injected with 50ml of 320mm
Cath LL-37 or phosphate-buffered saline (PBS) twice a day for
2 days. As expected, skin inflammation did not develop in the
mice pretreated with cromolyn. Mmp9 and Cxcl2 expressions
were significantly decreased in the cromolyn-treated mice
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Figure 1. Mast cell (MC) proteases and MMP-9 are crucial for rosacea inflammation development. (a) Human biopsy samples from healthy subjects (n¼ 6)
and rosacea subjects (n¼ 6) were assessed for CMA1 and MMP9 mRNA expressions. (b) The back skins of wild-type C57BL/6 (WT) and MC-deficient
(KitW-sh) mice were injected intradermally with Cath LL-37. Pictures were taken 72 hours after LL-37 injections. (c) Reverse transcriptase–PCR (RT-PCR) of
Mmp9 mRNA expression in skin biopsies from WT, WT MC-reconstituted KitW-sh (KitWsh), and KitW-sh. Mouse skin was injected with LL-37, LL-37 scrambled
peptide (LL-37 Scr), or PBS control (PBS) and harvested after 72 hours of observation. (d) Assessment of MMP protease activity in WT mouse skin after
challenge with PBS or Cath LL-37 at 50 and 320mM. (e) Mouse Chymase (Cma1) and mouse Tryptase (Tpsab1) were analyzed by RT-PCR in the skin from
WT or KitW-sh mice (KitWsh) at 0, 1, 4, and 24 hours after Cath LL-37 challenge. All of the experiments were repeated at least three times. Statistics:
Mann–Whitney test, one-way analysis of variance, and two-way analysis of variance. *Po0.05, **Po0.01, ***Po0.001 (n¼ 3). MMP, matrix
metalloproteinase.
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(Po0.01; Figure 3a). Consistent with Mmp9 mRNA expres-
sion, MMP activity in the tissue was also markedly decreased
by cromolyn pretreatment (Po0.01; Figure 3b). In addition,
frozen skin sections were stained with anti-MMP-9 and anti-
FceRI antibodies for the detection of MCs. The immunostain-
ing images showed that numerous MMP-9-positive MCs were
observed in Cath LL-37-treated mice, but not in cromolyn-
pretreated Cath LL-37 mice (Figure 3c left panel versus right
panel).
Human MC (huMC) proteases increase keratinocyte expression
of LL-37
Because we wanted to understand how human keratinocytes
respond to human MCs (huMCs), we examined a coculture
of normal human epidermal keratinocyte (NHEK) cells with
supernatant from huMCs, which had been degranulated by
compound 48/80. MMP and KLK enzyme activities were
significantly increased in NHEK cells when the cells were
cocultured for 24 hours with 100ml of huMC supernatant
6a b c
d
f g
e
4
2
0
***
M
m
p9
 
RT
-
PC
R
(C
T/G
AP
DH
)
24
Time (h)
Time (h)
50
24
Time (h)
50
24
24 28
Time (h)
Time (h)50
0
10
8
6
4
2
0
***
Cm
a1
 
RT
-
PC
R
(C
T/G
AP
DH
)
***
30
20
10
0
Tp
sa
b1
 
RT
-
PC
R
(C
T/G
AP
DH
)
M
M
P 
pr
ot
ea
se
 a
ct
ivi
ty
(V
ma
x s
–
1 )
D
eg
ra
nu
la
tio
n
(%
 on
 Tr
ito
n 
X)
0 6 24 PBS LL-37 20 nM 48/80
0.22
0.20
0.18
0.16
0.14
0.12
100
80
60
40
20
0
+MMPs substrate
+MMPs substrate
+MMP9 inhibitor (5 nM)
M
ou
se
 IL
-6
(pg
 m
l–1
)/1
06
 M
Cs
0
1,000
2,000
3,000
4,000
5,000 LL-37 20 nM
LL-37 40 nM
24410
Time (h)
24410
Kitwsh
WT
Il6
 R
T-
PC
R
(C
T/G
AP
DH
)
0
150
100
50
***
***
M
m
p9
 
RT
-
PC
R
(C
T/G
AP
DH
)
M
m
p1
a 
RT
-
PC
R
(C
T/G
AP
DH
)
KitWsh
WT
KitWsh
WT
KitWsh
WT
KitWsh
WT
0
15
10
5
PB
S SP
AD
M-
2
PA
CA
P
PB
S SP
AD
M-
2
PA
CA
P
PB
S SP
AD
M-
2
PA
CA
P
PB
S SP
AD
M-
2
PA
CA
P
PB
S SP
AD
M-
2
PA
CA
P
PB
S SP
AD
M-
2
PA
CA
P
PB
S SP
AD
M-
2
PA
CA
P
PB
S SP
AD
M-
2
PA
CA
P
*
*
**
*
Cm
a1
 
RT
-
PC
R
(C
T/G
AP
DH
)
Tp
sa
b1
 
RT
-
PC
R
(C
T/G
AP
DH
)
KitWsh
WT
0
80
60
40
20Cx
cl2
 
RT
-
PC
R
(C
T/G
AP
DH
)
PB
S SP
AD
M-
2
PA
CA
P
PB
S SP
AD
M-
2
PA
CA
P
**
Tn
f R
T-
PC
R
(C
T/G
AP
DH
)
KitWsh
WT
0
15
10
5
PB
S SP
AD
M-
2
PA
CA
P
PB
S SP
AD
M-
2
PA
CA
P
***
0
60
20
40
80
0
15
10
5
2.5
2.0
1.5
1.0
0.5
0.0
–0.5
Figure 2. Cathelicidin and neuropeptide pro-inflammatory activities are dependent on mast cell (MC) protease. (a–e) Cath LL-37 induces proinflammatory
responses. (a) In vitro mMCs expression of Metalloprotease 9 (Mmp9), Chymase (Cma1), and Tryptase (Tpsab1) after Cath LL-37 stimulation. (b) mMC Metallo-
protease activity (MMP protease activity) after Cath LL-37 challenge. (c) mMC degranulation (as b hexosaminidase release) in response to 24 hours of treatment
with 20 nM LL-37, positive control (48/80), and negative control (PBS). (d) ELISA IL-6 level (as pg ml1 per million MCs) in mMC culture 24 and 48 hours after 20
and 40 nM LL-37 treatment. (e) In vivo Il6 mRNA expression in mouse skin after 0, 1, 4, and 24 hours of Cath LL-37 challenge in WT- and MC-deficient
mice (KitWsh). (f–g) Neuropeptide-induced proinflammatory cytokine expression in skin is decreased in the absence of MCs in KitW-sh mice. WT and KitW-sh
(KitWsh) mice were injected with PBS or neuropeptide (SP, substance P; ADM-2, adrenomedullin-2; PACAP, pituitary adenylate cyclase–activating peptide)
intradermally. (f) mRNA expressions of mouse Chymase (Cma1), mouse Tryptase (Tpsab1), mouse metalloprotease 9 (Mmp9), and metalloprotease 1 (Mmp1a)
after NP challenge. (g) mRNA expressions of proinflammatory cytokines (Cxcl2 and Tnf) after NP challenge. Statistics: two-way analysis of variance. *Po0.05,
**Po0.01, ***Po0.001 (n¼ 3) repeated three times. mMC, mouse mast cell; NP, neuropeptides; WT, wild-type.
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(Po0.001; Figure 3d). As the activation of cathelicidin
in keratinocytes requires the active form of vitamin D3,
1,25(OH)2VD3 (Schauber et al., 2007), we also added
1,25(OH)2VD3 in the coculture model. The Cath LL-37
mRNA (CAMP) level was significantly increased after
coculture with huMC supernatant (Po0.001; Figure 3e).
Therefore, this confirms that, although LL-37 activates MCs,
MC supernatants increase protease production in human
skin epidermis, amplifying the inflammation and creating a
vicious cycle.
Stabilization of MCs could be a target therapy for
erythematotelangiectatic rosacea
To test whether our results were relevant in humans, 10
randomized adults with erythematotelangiectatic rosacea
were chosen to apply a solution containing either the MC
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stabilizer (4% cromolyn sodium) or placebo, topically to their
face, twice daily. Six tape strips were obtained from both right
and left cheeks, at the time of first visit (v1) and last visit (v4).
Facial erythema was clinically assessed by a blind investigator
using the Clinician’s Erythema Assessment (CEA). None of the
subjects presented with papules and pustules; therefore, after
8 weeks (v4), only facial erythema levels decreased in the
cromolyn treatment group (data not shown). MMP activity was
significantly decreased in the cromolyn treatment group
(Figure 3f), whereas KLK activity (Figure 3g) and Cath LL-37
protein levels (Figure 3h) only showed a mild decrease.
DISCUSSION
An abnormal increase in the free form of hCAP18 (Cath LL-37)
antimicrobial peptide in human skin is crucial for the
pathogenesis of rosacea (Yamasaki et al., 2007). MCs are
one of the primary sources of cathelicidin in the skin, and they
are also the main source of enzymes that activate cathelicidin
to its active form (Cath LL-37; Di Nardo et al., 2003). Previous
studies have reported that MC activity increases in the skin of
rosacea patients (Yamasaki et al., 2007). However, a great
number of questions remain regarding the manner in which
inflammatory signals are transmitted from the epidermis to
vessels and inflammatory cells. In the present study, we found
that MC proteases and Mmp9 mRNAs are highly expressed in
skin from rosacea patients (Figure 1a). Therefore, we hypothe-
size that after Cath LL-37 has been released from the
epidermis in rosacea skin it in turn activates MCs to induce
inflammation and neutrophil recruitment, which results in
more Cath LL-37.
We next demonstrated that Cath LL-37 peptide strongly
activates skin MCs to release proteases that are crucial in the
development of rosacea-like inflammation in vivo. We clearly
showed that in MC-deficient mice intradermal Cath LL-37
injections did not generate all of the dermal events that are
usually found in rosacea, including inflammation and MMP-9
activation. To more strongly support our hypothesis that MCs
are crucial in the generation of skin inflammation, we also
reconstituted MC-deficient mice with WT MCs and showed
that the rosacea-like inflammation phenotype reappears. More-
over, we demonstrated the specificity of Cath LL-37 peptide in
MC activation by showing that injection of a scrambled
peptide did not induce inflammation (Figure 1c). This result
is nicely paralleled by our in vitro experiments, where we
observed an increase in MMP-9 protease activity in the culture
supernatant of Cath LL-37-treated mMCs (Figure 2b). Our
hypothesis that MMP-9 is involved in rosacea pathogenesis is
supported by the recent discovery that doxycycline, which is
an effective therapeutic for improving rosacea symptoms,
inhibits MMPs directly (Kanada et al., 2012).
Any signal (especially from neurogenic factors) that induces
the activation of MCs results in the amplification of the
inflammatory response, and thus we propose that MCs are
the missing link between flaring and inflammation in rosacea.
Tryptase activates PAR-2 on nerve endings and keratinocytes,
which in turn causes the release of NPs (Steinhoff et al., 1999).
On the other hand, activated PAR-2 stimulates MC mediator
release (eg, histamine release) during cutaneous inflammation
(Aubdool and Brain, 2011). Transient receptor potential
vanilloid 1 (TRPV1) and ankyrin 1 (TRPA1), which are highly
expressed on primary sensory neuron endings, are also strongly
present in rosacea skin (Aubdool and Brain, 2011). Activated
PAR-2 enhances these receptors in the vascular endothelial
cells and immune cells (Aubdool and Brain, 2011), explaining
how MCs might be linked to rosacea flashing and erythema.
PACAP is a neuropeptide that has been shown to be one of the
main mediators in the response to psychological stress and is
abundantly expressed in rosacea-affected skin (Schwab et al.,
2011). It has been reported that PACAP is not only able to
induce neuronal inflammation, but also edema and flushing in
human skin (Roosterman et al., 2006). Our in vivo experiments
have proven that intradermal injections of PACAP significantly
induce the expression of the MC proteases, Mmp1a, and
Mmp9 in WT mice but not in MC-deficient mice (Figure 2f).
Moreover, markedly increased expressions of the proinflam-
matory cytokines Tnf and Cxcl2 were observed in skin after
PACAP challenge (Figure 2g). Although it is well known that
neuronal activation results in the release of MC-derived
histamine and leukotriene, our study also confirms that PACAP
increases the expressions of Mmp1 and Mmp9, which are
activators of hCAP18 processing to Cath LL-37. In our last
experiment, we also proved that activated MCs release
enzymes that increase LL-37 expression in keratinocytes.
Therefore, we have proven a link between PACAP and Cath
LL-37. Consequently, these peptides work synergistically in the
development of rosacea symptoms in human skin.
As MC activation has an important role in rosacea inflam-
mation, we examined whether the stabilization of MCs can
directly reduce skin inflammation in WT mice. In our
research, mice injected intraperitoneally with cromolyn did
not develop rosacea-like skin inflammation after Cath LL-37
challenge. Moreover, MMP activity, Mmp9 and Cxcl2 mRNA
expressions, and MMP-9/MC immunostaining in the skin were
significantly decreased compared with mice not treated with
cromolyn. Cxcl2 is the mouse homolog of human IL8 and is
crucial for neutrophil recruitment in vivo.
Few case reports have cited MC stabilizers as a potential
treatment for rosacea and Morbus Morbihan (Hu et al., 2012);
however, we have now determined that MC stabilizers
actually block MC-induced inflammation and have the
potential to be developed as therapeutics for the treatment
of rosacea. Skin MCs are localized near keratinocytes and
sensory nerve endings in the epidermis and dermis; therefore,
MC proteases (chymase and tryptase), histamine, MMP-9, and
proinflammatory cytokines amplify the progression of skin
inflammation, tissue remodeling, and angiogenesis (Coussens
et al., 2000). Chymase, an MC-specific protease, can not only
activate pro-MMP-9 and other MMP cascades (Tchougounova
et al., 2005) but can also inhibit enzyme degradation by
TIMP-1, further stabilizing MMP-9. From our observations of
the mouse model of rosacea, we have proven that proinfla-
mmatory peptides generated from epidermal keratinocytes
and sensory nerve endings activate dermal MCs, which in
turn amplify skin inflammation and angiogenesis via their
secretion of proteases, MMP-9, and proinflammatory
cytokines. In addition, our in vitro data of NHEK cells
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strongly support the hypothesis that protease generated from
MCs will induce dermal inflammation and increase the
production of enzymes from the epidermal layer able to
generate LL-37, with the result of creating a proinflammatory
loop (Figure 3d and e). The release of MC proteases activates
MMP-9 and KLKs in NHEKs, which results in the generation of
additional active Cath LL-37 peptide.
In conclusion, rosacea features cannot be generated in
mouse skin in the absence of MCs or when MCs have been
pharmacologically stabilized. LL-37 and NPs activate MCs;
activated huMCs, in turn, increase NHK expression and
processing of LL-37, making huMCs central in amplifying
rosacea inflammation and symptoms, especially erythema,
flushing, and telangiectasia. Moreover, our preliminary results
from a limited clinical trial supports the hypothesis that MC
stabilizers can change metalloproteinase activity in rosacea in
humans. On the basis of these observations, MC stabilizers
should be considered as a future therapy in the treatment and
prevention of rosacea symptoms.
MATERIALS AND METHODS
Reagents
Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 fluorogenic substrate
and 6-Amidino-2-naphthy-4-guanidinobenzoate dimethanesulfonate
were purchased from Enzo Life Sciences (Plymouth Meeting, PA).
Cromolyn sodium and substance P fragment were purchased from
Sigma-Aldrich (St Louis, MO). Adrenomedullin-2 and PACAP
were purchased from AnaSpec (Fremont, CA). 4-methylumbelliferyl-
2-acetamide-2-deoxy-b-D-glucopyranoside was purchased from Cal-
biochem (EMD Millipore; Billerica, MA). MMP-9-specific inhibitor I,
chymotryptase-specific fluorogenic substrate, and Pierce BCA protein
assay kit were purchased from Thermo Fisher Scientific (Chicago, IL).
Human specimens
All the procedures involving human subjects were approved by the
University of California San Diego Institutional Review Board under
IRB number 071032 in accordance with adherence to the Helsinki
Guidelines, and written informed patient consent was obtained. Skin
biopsies (2 mm) were taken from the faces of healthy and rosacea
subjects, as well as tape strips from the face of erythematotelangiec-
tatic rosacea subjects in the dermatology clinic at the University of
California, San Diego. Ten randomized adults with erythematotelan-
giectatic rosacea were applied a water-based solution containing
either 4% cromolyn sodium or placebo, topically to their face twice a
day, for 8 weeks. A clinical evaluation was performed at each visit.
A total of six tape strips were obtained from right and left cheek at
each of the first visit and the final visit. Facial erythema was clinically
assessed by a blind investigator using the CEA, which grades erythema
on a five-point scale: 0¼ none (no redness), 1¼mild (slight pinkness),
2¼moderate (definite redness), 3¼ significant (marked erythema),
and 4¼ severe (fiery redness). At each visit, the CEA was performed
on five different facial regions: right cheek, left cheek, nose, chin, and
glabella. The subject’s final CEA score for each visit was calculated by
summing the CEA score of each of the five facial regions for that visit.
Mouse experiments
B6.Cg-KitW-sh/HNihrJaeBsmJ MC-deficient mice were bred at our
facility. Institutional Animal Care and Use Committee (IACUC) of
UC San Diego approved all animal experiments. B6.Cg-KitW-sh/
HNihrJaeBsmJ (KitW-sh) the W-sash (Wsh) inversion mutation have
MC deficiency, but lack anemia and sterility. Adult KitW-sh mice
had a profound deficiency in MCs in all tissues examined but normal
levels of major classes of other differentiated lymphoid cells.
MC-deficient mice and WT mice (C57BL/6) were used for these
experiments. WT- and MC-deficient mice were shaved 24 hours
before intradermal injection with 50ml of 50mM or 320mM Cath
LL-37 or filtered PBS (n¼ 3) twice a day for 2 days. Skin biopsies were
taken after 72 hours of observation, and tissues were immersed
immediately into RNA stabilization reagent (RNAlater; QIAGEN
science, Germantown, MD). Total RNA was extracted and purified
using the RNeasy Mini Kit (QIAGEN science). mRNA expressions of
proteases and cytokines were assessed by reverse transcriptase–PCR
(RT-PCR). For the time-course observation of chymase and tryptase
mRNAs, skin biopsies of WT and MC-deficient mice were taken at 1,
4, and 24 hours after Cath LL-37 injection and analyzed by RT-PCR.
For the neuropeptide challenge experiment, 0.1mM neuropeptide or
PBS was injected into WT mice and MC-deficient mice intradermally.
Skin biopsies were taken 6 hours after injection and analyzed by
RT-PCR.
For the MC stabilizer experiment, cromolyn sodium (10 mg kg 1
body weight, per day) (Sigma-Aldrich) was diluted in filtered PBS and
injected intraperitoneally into WT mice for 4 days. After 4 days of
treatment, 50ml of 320mM Cath LL-37 or PBS was injected intrader-
mally twice a day for 2 days while continuing daily cromolyn
treatment. At 72 hours after the beginning of the Cath LL-37 injec-
tions, skin biopsies were taken and analyzed for mRNA expression
and protease activity.
MCs
Primary MCs were generated from mouse bone marrow and cultured
in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with
10% inactivated fetal bovine serum (Thermo Fisher Scientific), 25 mM
HEPES (pH 7.4), 4 mM L-glutamine, 0.1 mM nonessential amino acids,
1 mM sodium pyruvate, 50 mM 2-ME, 100 IU ml 1 penicillin, and
100 mg ml 1 streptomycin, recombinant murine IL-3 (R&D Systems,
Minneapolis, MN), and recombinant murine stem cell factor (R&D
Systems). MMCs derived from bone marrow cells that are cultured
with stem cell factor and IL-3 become mature in vitro. After 4 weeks,
MCs were consistently generated, as confirmed by the expression of
CD117 (c-Kit) and FceRI. Cell maturation was confirmed by meta-
chromatic staining with toluidine blue. The purity of MCs was greater
than 98%. MCs were cultured in Stemline II Hematopoietic Stem Cell
Expansion Medium (Sigma-Aldrich).
BMMC reconstitution in KitW-sh mice
4 106 Cells of C57BL/6 mature BMMCs were diluted in filtered PBS
and injected into the shaved back skin of 6-week-old C57BL/6-KitW-sh
mice (400ml; 8 50ml injections) intradermally. After 6 weeks, MCs
were confirmed as resident cells in skin by toluidine blue staining.
Measurement of protease activity
MMP activities were determined in 0.1 M Tris-HCl (pH 7.5) contain-
ing 150 mM NaCl, 10 mM CaCl2, 0.1 mM ZnCl2, 0.05% (v/v) Brij35,
and 0.1% (w/v) PEG6000. Protein extracts were normalized with a
BCA assay kit. Total-MMP activity was determined by adding total-
MMP fluorogenic substrate (5mM) Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-
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Arg-NH2 (Enzo Life Sciences) to protein extracts, incubating for
2 hours at 37 1C, and subsequently measuring the activity (Vmax
per second) at a fluorescence excitation wavelength of 328 nm and
an emission wavelength of 400 nm in a fluorescence plate reader
(Gemini EM microplate spectrofluorometer; Molecular Devices,
Sunnyvale, CA). To determine MMP-9 activity, MMP-9-specific
inhibitor I (Thermo Fisher Scientific) was added to protein extracts.
Chymase and tryptase activities were assayed in 0.1 mM Tris-HCl (pH
8.0) and 200 mM NaCl. Chymase activity was monitored by adding
chymotryptase-specific fluorogenic substrate (Thermo Fisher Scienti-
fic; 5mM) to protein extracts, incubating for 2 hours at 37 1C, and
subsequently measuring the activity (Vmax per second) at a fluores-
cence excitation wavelength of 380 nm and an emission wavelength
of 460 nm. Tryptase activity was determined by adding serine
protease–specific fluorogenic substrate (Boc-Phe-Ser-Arg-AMC,
Bachem Bioscience, Torrance, CA) (5mM) with/without ABESF (Sigma)
to protein extracts, incubating for 2 hours at 37 1C, and subsequently
measuring relative fluorescence units at a fluorescence excitation
wavelength of 354 nm and an emission wavelength of 422 nm.
Proteins in skin tissues or cells were normalized with the Pierce
BCA protein assay kit (Thermo Fisher Scientific).
Semiquantitative real-time PCR
cDNA was synthesized from RNA using the iScript cDNA Synthesis
Kit (BioRad, Hercules, CA) according to the manufacturer’s protocol.
Synthesized cDNA was normalized using a NanoDrop spectrophot-
ometer (Thermo Fisher Scientific). TaqMan Gene Expression Assays
(Applied Biosystems ABI, Foster City, CA) were used to analyze the
expressions of human MMP9, human CMA1, human CAMP, mouse
Mmp9, mouse Mmp1a, mouse Klk5, mouse Klk6, mouse Tpsab1,
mouse Cma1, mouse Cxcl2, and mouse Tnf, according to the
manufacturer’s instructions (Applied Biosystems). GAPDH and Gapdh
mRNA were used as an internal control to validate RNA for each
sample. mRNA expression was calculated as the relative expression
to GAPDH or Gapdh mRNA, and all data are presented as fold
change of each control.
MC degranulation assay
Degranulation percentage was assessed by measuring the activity of
b-hexosaminidase in the supernatants of 1 105 MCs in 200 ml of
Tyrode’s buffer incubated for 1 hour with 0 or 20 nM Cath LL-37, 1%
Triton X-100, and 10mg ml 1 compound 48/80 (Sigma-Aldrich) as a
positive control. For each sample assayed, supernatant aliquots (25ml)
were mixed with substrate solution (50ml), which consisted of 10 mM
4-methylumbelliferyl-2-acetamide-2-deoxy-b-D-glucopyranoside (Cal-
biochem) in 0.1 M sodium citrate buffer (pH 4.5), and were incubated
for 30 min at 37 1C. The reaction was then stopped by adding 50ml of
0.4 M glycine (pH 10.7). The reaction mixtures were excited at
365 nm and measured at 460 nm in a fluorescence plate reader
(Gemini EM microplate spectrofluorometer; Molecular Devices). To
determine the total cellular content of this enzyme, an equivalent
number of cells were lysed with 1% Triton X-100 and 10mg ml 1
compound 48/80 (Sigma-Aldrich). The release of b-hexosaminidase
was calculated as the percentage of the total enzyme content.
Cath LL-37 stimulation of mMCs
mMCs were challenged in vitro with 10mg ml 1 Cath LL-37. The
cells were harvested at 0, 5, and 24 hours, and mRNA was extracted
and assessed by RT-PCR for mouse metalloprotease 9 (Mmp9), mouse
Chymase (Cma1), and mouse Tryptase (Tpsab1) expression. mMC
metalloprotease activity was assessed at 6 and 24 hours after Cath
LL-37 challenge, as previously described. mMC degranulation in
response to LL-37 was assessed at 24 hours by b-hexosaminidase
release, as described; positive control (48/80) and negative control
(PBS) were added. For IL-6-level evalulation, mMcs were treated with
20 and 40 nM LL-37 for 24 and 48 hours. ELISA (ELISA MAX Deluxe;
BioLegend, San Diego, CA) was used to determine mouse IL-6 in all
supernatants of cell culture medium according to the manufacturer’s
instructions. All supernatant samples were normalized by the Pierce
BCA protein assay kit (Thermo Fisher Scientific) to total protein
content of the sample.
MC supernant–NHEK stimulation
At 2 days after confluence in Epilife medium (Thermo Fisher
Scientific) with 0.06 mM CaCl2, NHEK cells were stimulated with
supernatant from degranulated human cord blood–derived MCs in
saline buffer, or saline buffer alone. MMP and KLK protease activities
in the NHEKs were evaluated after 24 hours. RT-PCR was evaluated
after 6 hours from the MC supernatant addition. For RT-PCR Cath LL-
37 mRNA (CAMP) expression, 100 nM 1,25(OH)2VD3 was added. All
of the experiments were repeated at least three times.
Fluorescence immunohistochemistry
Mouse skin frozen sections were fixed with acetone, washed in 1X
PBS, blocked with 5% goat serum/1% BSA for 30 minutes, and
incubated with anti-MMP-9 polyclonal antibody (ABBIOTEC, San
Diego, CA) as a primary antibody (diluted 1:200). FITC-conjugated
goat antibody to rabbit IgG (Molecular Probes, Grand Island, NY) was
used as a secondary antibody (diluted 1:1,000) and was incubated for
40 minutes. For FceRI detection, we used anti-mouse FceRI PE
(eBioscience, San Diego, CA). We mounted sections in ProLong
Anti-Fade reagent (Molecular Probes) with 40, 6-diamidino-2-pheny-
lindole. After overnight incubation at 4 1C in the dark, images were
obtained using a Zeiss LSM510 laser scanning confocal microscope
coupled with an Axiovert 100 inverted-stage microscope.
Statistical analyses
The data are presented as means ±SEM. To determine the signifi-
cance between two or more groups, one-way and two-way analysis
of variance or the two-tailed t-test was used and analyzed by
GraphPad Prism4 (GraphPad Software, La Jolla, CA). For all statistical
tests, Po0.05 was considered statistically significant.
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